Regeneron Inc. announces receipt of Eylea’s EU approval for macular edema secondary to Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the receipt of European Union approval for aflibercept (marketed as Eylea) for the treatment of visual impairment due… Read More »Regeneron Inc. announces receipt of Eylea’s EU approval for macular edema secondary to Retinal Vein Occlusion